Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis and glutamate.

Anthony J Groom1, Terence Smith, Lechoslaw Turski

  • 1Eisai London Research Laboratories, University College London, Bernard Katz Building, Gower Street, United Kingdom.

Annals of the New York Academy of Sciences
|July 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2023
Same author

AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" a translational review and therapeutic perspectives.

Restorative neurology and neuroscience·2020
Same author

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2015
Same author

Direct measurement and characterization of active photosynthesis zones inside wastewater remediating and biofuel producing microalgal biofilms.

Bioresource technology·2014
Same author

Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels.

American journal of physiology. Endocrinology and metabolism·2011
Same author

Glutamate receptors in laryngeal cancer cells.

Anticancer research·2011

Glutamate AMPA antagonists show promise for treating multiple sclerosis (MS). These drugs reduced neurological disability in rodent models, suggesting a new therapeutic avenue for this disabling immune-mediated disorder.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a disabling immune-mediated neurological disorder with no adequate therapy.
  • Glutamate's role in neurodegenerative diseases is increasingly recognized.
  • Current MS treatments include anti-inflammatory, immunosuppressive, and immunomodulatory measures.

Purpose of the Study:

  • To review glutamatergic system changes in MS.
  • To investigate the effects of glutamate AMPA antagonists in rodent models of MS.

Main Methods:

  • Reviewed literature on glutamatergic system in MS.
  • Administered diverse competitive and non-competitive AMPA antagonists in acute and chronic rodent MS models.
  • Evaluated effects in adoptive transfer, chronic, and relapsing-remitting MS models.

Related Experiment Videos

Main Results:

  • AMPA antagonists reduced neurological disability in acute experimental autoimmune encephalomyelitis (EAE) models.
  • AMPA antagonists were effective in chronic and relapsing EAE models in rats and mice.
  • Short-term AMPA antagonist therapy provided sustained benefits into progressive phases.

Conclusions:

  • Glutamate AMPA antagonists demonstrate therapeutic potential for reducing neurological disability in MS.
  • Complementing existing MS therapies with AMPA antagonists may improve patient outcomes.
  • Targeting the glutamatergic system offers a novel strategy for MS treatment.